According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...

U.S. suspends Ixchiq vaccine license due to serious side effects, raising concerns over chikungunya virus spread globally.

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

Investing.com -- Valneva SE ADR (NASDAQ:VALN) stock tumbled 20.4% premarket Monday after the U.S. Food and Drug ...

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...